

PROVIDER ALERT

Update Regarding COVID-19 Codes

On October 2, 2020, the Department of Health Care Services (DHCS) notified managed care plans (MCPs), like CalOptima, that there has been a delay in the deployment of Healthcare Common Procedure Coding System (HCPCS) codes, Current Procedural Terminology (CPT) and International Classification of Diseases, 10th Revision (ICD-10) codes related to COVID-19.

Additionally, DHCS provided further clarification that only the codes in the attached table with a **deployment date of September 19th are impacted**; all other codes are fully implemented and billable. Please note that the effective date refers to when the code can be used for billing (i.e. the service date must be on or after the effective date), while the **deployment** date refers to the date the PACES system at DHCS will recognize the codes for encounter data submissions.

DHCS will notify MCPs once a new deployment date is available for those impacted codes.

COVID-19 Code Deployment Dates

Code Set	Code	Description	Service Code Effective Date	Code List Version	System Deployment Date
HCPCS	U0001	CDC 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel	2/4/2020	9.2.7	3/20/2020
HCPCS	U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-CDC	2/4/2020	9.2.7	3/20/2020
HCPCS	U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.	4/14/2020	9.2.9	with 9.2.10 on 7/17/2020
HCPCS	U0004	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.	4/14/2020	9.2.9	with 9.2.10 on 7/17/2020
HCPCS	C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	3/1/2020	9.2.9	with 9.2.10 on 7/17/2020
HCPCS	G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	3/1/2020	9.2.8	5/15/2020

PROVIDER

ALERT

COVID-19 Code Deployment Dates (cont.)

Code Set	Code	Description	Service Code Effective Date	Code List Version	System Deployment Date
HCPCS	G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars- cov-2) (coronavirus disease [covid-19]) from an individual in a SNF or by a laboratory on behalf of a HHA, any specimen source	3/1/2020	9.2.8	5/15/2020
HCPCS [modifier]	CS	Cost-sharing for specified COVID-19 testing-related services that result in an order for or administration of a COVID-19 test	4/1/2020	9.2.8	5/15/2020
CPT®	0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.	5/20/2020	9.2.10	7/17/2020
CPT®	0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including sever acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	6/25/2020	9.2.11	8/6/2020
CPT®	0224U	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed	6/25/2020	9.2.11	8/6/2020
CPT®	87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	3/13/2020	9.2.7	3/20/2020
CPT®	86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	4/10/2020	9.2.8	5/15/2020

PROVIDER ALERT

COVID-19 Code Deployment Dates (cont.)

Code Set	Code	Description	Service Code Effective Date	Code List Version	System Deployment Date
CPT®	86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	4/10/2020	9.2.8	5/15/2020
CPT®	87426	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV2 [COVID-19])	6/25/2020	9.2.11	8/6/2020
ICD-10 CM	U07.1	COVID-19 [virus, identified]	4/1/2020	9.2.8	5/15/2020
ICD-10 PCS	XW013 F5	Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5	8/1/2020	9.2.12	9/19/2020
ICD-10 PCS	XW033 E5	Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5	8/1/2020	9.2.12	9/19/2020
ICD-10 PCS	XW033 F5	Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5	8/1/2020	9.2.12	9/19/2020
ICD-10 PCS	XW033 G5	Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5	8/1/2020	9.2.12	9/19/2020
ICD-10 PCS	XW033 H5	Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5	8/1/2020	9.2.12	9/19/2020
ICD-10 PCS	XW043 E5	Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5	8/1/2020	9.2.12	9/19/2020
ICD-10 PCS	XW043 F5	Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5	8/1/2020	9.2.12	9/19/2020
ICD-10 PCS	XW043 G5	Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5	8/1/2020	9.2.12	9/19/2020

PROVIDER

ALERT

COVID-19 Code Deployment Dates (cont.)

Code Set	Code	Description	Service Code Effective Date	Code List Version	System Deployment Date
ICD-10 PCS	XW043 H5	Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5	8/1/2020	9.2.12	9/19/2020
ICD-10 PCS	XW0DX F5	Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5	8/1/2020	9.2.12	9/19/2020
ICD-10 PCS	XW133 25	Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5	8/1/2020	9.2.12	9/19/2020
ICD-10 PCS	XW143 25	Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5	8/1/2020	9.2.12	9/19/2020